×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VNDA – vanda pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VNDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/9
11:19 am
vnda
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [Yahoo! Finance]
4/9
11:10 am
vnda
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [TheStreet.com]
Low
Report
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines [TheStreet.com]
4/9
11:02 am
vnda
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
Low
Report
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
4/8
05:03 pm
vnda
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists [TheStreet.com]
Low
Report
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists [TheStreet.com]
4/8
04:44 pm
vnda
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
Low
Report
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
3/19
04:55 pm
vnda
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods [Yahoo! Finance]
High
Report
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods [Yahoo! Finance]
3/19
04:34 pm
vnda
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
High
Report
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
3/13
08:33 am
vnda
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag [Yahoo! Finance]
Medium
Report
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/11/2026
04:01 pm
vnda
vanda pharmaceuticals inc.
MISS
Report
-17.6%
vanda pharmaceuticals inc.
10/29/2025
04:01 pm
vnda
vanda pharmaceuticals inc.
MISS
Report
-20.1%
vanda pharmaceuticals inc.
7/31/2025
07:30 am
vnda
vanda pharmaceuticals inc.
MISS
Report
-5.3%
vanda pharmaceuticals inc.
5/7/2025
04:01 pm
vnda
vanda pharmaceuticals inc.
BEAT
Report
-3.7%
vanda pharmaceuticals inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
04:31 pm
vnda
Form 8-K Vanda Pharmaceuticals For: Mar 29
Low
Report
Form 8-K Vanda Pharmaceuticals For: Mar 29
3/27
01:56 pm
vnda
Form SCHEDULE 13G/A Vanda Pharmaceuticals Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Vanda Pharmaceuticals Filed by: VANGUARD GROUP INC
3/10
04:47 pm
vnda
Form 8-K Vanda Pharmaceuticals For: Mar 10
Medium
Report
Form 8-K Vanda Pharmaceuticals For: Mar 10
3/4
06:54 pm
vnda
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Williams Timothy
Medium
Report
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Williams Timothy
3/4
06:53 pm
vnda
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Moran Kevin Patrick
Medium
Report
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Moran Kevin Patrick
3/4
06:52 pm
vnda
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Wijkstrom Joakim
Medium
Report
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Wijkstrom Joakim
3/4
06:52 pm
vnda
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Polymeropoulos Mihael Hristos
Medium
Report
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Polymeropoulos Mihael Hristos
3/4
06:51 pm
vnda
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Birznieks Gunther
Medium
Report
Form 4 Vanda Pharmaceuticals For: Mar 02 Filed by: Birznieks Gunther
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/31
Q2/2019 6/30/2019 EPS 0.280 ZacksConsensus -0.030 ActVsEst 0.310 - Beat
26.8%
4/2 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.1%
11/6 Q3/2019 9/30/2019 EPS 1.880 ZacksConsensus 0.070 ActVsEst 1.810 - Beat 10.6%
8/19 FDA rejects Vanda's Hetlioz for jet lag disorder [Seeking Alpha] 8.9%
3/24 Form 3 Vanda Pharmaceuticals For: Mar 15 Filed by: Moran Kevin Patrick 7.3%
4/15 Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine 6.9%
2/25 Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.8%
9/10 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 6.2%
2/14 Form SC 13G/A Vanda Pharmaceuticals Filed by: Consonance Capital Management LP 5.3%
2/28 Form 4 Vanda Pharmaceuticals For: Feb 26 Filed by: Birznieks Gunther 3.9%
4/2 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.1%
11/6 Q3/2019 9/30/2019 EPS 1.880 ZacksConsensus 0.070 ActVsEst 1.810 - Beat 10.6%
8/19 FDA rejects Vanda's Hetlioz for jet lag disorder [Seeking Alpha] 8.9%
3/24 Form 3 Vanda Pharmaceuticals For: Mar 15 Filed by: Moran Kevin Patrick 7.3%
4/15 Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine 6.9%
2/25 Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.8%
9/10 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 6.2%
2/14 Form SC 13G/A Vanda Pharmaceuticals Filed by: Consonance Capital Management LP 5.3%
2/28 Form 4 Vanda Pharmaceuticals For: Feb 26 Filed by: Birznieks Gunther 3.9%
TOP News Decliners
3/13
Form 8-K Vanda Pharmaceuticals For: Mar 12
-20.9%
11/7 Form 10-Q Vanda Pharmaceuticals For: Sep 30 -11.9%
2/20 Form 8-K Vanda Pharmaceuticals For: Feb 18 -9.1%
7/24 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $17.00 price target on the stock. -7.0%
4/15 Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia -6.2%
1/11 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. -5.6%
2/26 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
4/10 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. -4.7%
3/23 Florida man with coronavirus claims anti-malarial drug saved his life [FOX News] -4.5%
7/22 Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder -4.5%
11/7 Form 10-Q Vanda Pharmaceuticals For: Sep 30 -11.9%
2/20 Form 8-K Vanda Pharmaceuticals For: Feb 18 -9.1%
7/24 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $17.00 price target on the stock. -7.0%
4/15 Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia -6.2%
1/11 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock. -5.6%
2/26 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
4/10 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. -4.7%
3/23 Florida man with coronavirus claims anti-malarial drug saved his life [FOX News] -4.5%
7/22 Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: